Key Points
-
Interested in Grifols, S.A.? Here are five stocks we like better.
-
Grifols delivered solid third-quarter growth:Revenue rose 8.4% to €2.04 billion, while adjusted EBITDA increased 9.8% to €538 million and the margin expanded to 26.4%. Management maintained its full-year EBITDA margin target of 25%.
-
Cash generation and leverage improved:Nine-month free cash flow before acquisitions increased 59% to €298 million, and total net leverage fell below 4 times adjusted EBITDA. The board also approved an interim dividend of €0.15 per share.
-
Immunoglobulin growth offset continued albumin weakness:IG revenue rose 11.3% in the quarter, but albumin revenue declined 13.2% amid China-related inventory, pricing and prescribing pressures. Management expects albumin conditions to stabilize gradually, while Egypt's expanding plasma platform is expected to contribute more materially from 2027 onward.
-
3 Health Care Stocks That Could Double by Year End
Grifols (NASDAQ:GRFS) reported third-quarter 2026 results marked by revenue growth, expanding profitability, stronger free cash flow and lower leverage, while management reiterated its full-year financial targets despite continued weakness in China's albumin market.
Chief Executive Officer Nacho Abia said the company's core Biopharma business drove the quarter, with Biopharma revenue increasing 10.3% at constant currency and total group revenue rising 8.4% to €2.04 billion. For the first nine months, revenue reached €5.614 billion, up 4.6% at constant currency.
→ Starbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch)
Adjusted EBITDA was €538 million in the third quarter, up 9.8% from a year earlier, while the adjusted EBITDA margin expanded 60 basis points to 26.4%. Nine-month adjusted EBITDA totaled €1.392 billion, with a 24.8% margin. Grifols maintained its full-year adjusted EBITDA margin target of 25%.
Cash Flow, Leverage and Dividend
Chief Financial Officer Rahul Srinivasan said improved operating performance was increasingly translating into cash generation and balance-sheet improvement. Free cash flow before mergers and acquisitions reached €298 million in the first nine months, a 59% increase, or €110 million higher than the prior-year period.
→ MarketBeat Week in Review – 10/26 - 10/30
The company's total net leverage declined to 3.98 times adjusted EBITDA, falling below 4 times after standing at 5.5 times in June 2024, according to management. Secured net leverage was 2.5 times, while liquidity stood at €2.14 billion. Grifols said it has no significant debt maturities until the fourth quarter of 2028.
The board approved an interim dividend of €0.15 per share, payable in early December 2026. Abia said the decision reflected the company's year-to-date performance and confidence in upcoming quarters.
→ 3 Robotics ETFs, 3 Different Ways to Bet on Humanoid Robots
Management said some favorable timing effects contributed to year-to-date free cash flow and would unwind in the fourth quarter, but reiterated confidence in meeting its 2026 free-cash-flow target and its objectives through 2027.
Immunoglobulins Lead Growth as Albumin Remains Under Pressure
Immunoglobulin, or IG, remained Grifols' principal growth driver. IG revenue rose 11.3% at constant currency in the third quarter and 12.3% in the first nine months. Revenue from subcutaneous IG products increased 40.3% in the quarter and 25.6% year to date.
Abia attributed the growth to demand across primary and secondary immunodeficiencies and chronic inflammatory demyelinating polyneuropathy, or CIDP. He said Grifols' portfolio of intravenous and subcutaneous therapies supported a diversified growth profile rather than dependence on a single product or treatment type.
Alpha-1 and Specialty Proteins revenue increased 18.2% in the quarter, aided by a significant contribution from HyperRAB. Management maintained its expectation for mid-single-digit growth in that business for the full year, noting that Alpha-1 treatment numbers improved as patient access conditions normalized following a difficult reauthorization period earlier in the year.
Albumin remained the principal challenge. Revenue from the product declined 13.2% in the quarter and 13.9% through nine months at constant currency, reflecting prescribing restrictions, elevated channel inventories and pricing pressure in China. Abia said sellout trends had begun to improve, but the improvement had not yet led to a sustained recovery in reported sales.
Management expects the inventory adjustment to take time and said market conditions may become more stable in 2027, when comparisons will be against the depressed 2026 period. Grifols is seeking to broaden albumin distribution in China through tier-two hospitals and retail pharmacies while also expanding in markets outside China.
Egypt Plasma Platform and Diagnostics Strategy
Grifols continued to build its plasma collection and processing platform in Egypt, where the company achieved self-sufficiency in factor VIII, albumin and IG last year. Monthly collection volume has nearly doubled since the start of 2026, and the company expects to collect about 1 million liters this year.
The company currently operates 18 plasma collection centers in Egypt and expects to reach 20 by the first quarter of 2027. Over the coming years, it plans to add another 20 centers to support annual collection capacity of 3 million liters.
Management said European Medicines Agency approval enables Egyptian plasma to be incorporated into Grifols' global sourcing network. Srinivasan said the financial contribution from Egypt was still small in 2026 but should become more visible in 2027 and increase further in 2028 and 2029 as volumes rise.
In Diagnostics, revenue declined 7% through nine months because of the dissolution of the QuidelOrtho joint business. Excluding that impact, underlying Diagnostics revenue grew 2.3%, supported by blood typing solutions and improved performance in NAT testing. The company also cited progress on its Evanzys IH, ISARD and MUNDAKA platforms.
Outlook and Strategic Review
Grifols cautioned that fourth-quarter Biopharma growth is expected to be modest compared with a strong fourth quarter of 2025. Srinivasan said the company manages the business on a full-year basis and is focused on optimizing EBITDA growth and margin expansion rather than pursuing volume growth alone, particularly while albumin remains weak.
The company is continuing to assess a potential initial public offering of its U.S. Biopharma business. Srinivasan said the board is conducting a diligent review and that he does not expect an update before 2027, adding that the board's focus is on unlocking value.
Separately, Grifols said it voluntarily paused plasma collection at its 17 Canadian centers in mid-August before beginning a phased resumption in coordination with Health Canada and Canadian Blood Services. Commercial operations in Canada continued during the pause through plasma sourced from the U.S.
During the question-and-answer session, Abia also addressed reports of increased regulatory scrutiny involving immunoglobulin products, saying the matter was industrywide rather than focused on Grifols and that the company works with regulators on patient-safety issues and adverse events.
About Grifols (NASDAQ:GRFS)
Grifols SA is a global healthcare company headquartered in Barcelona, Spain, specializing in plasma-derived medicines and diagnostic technologies. The company develops, manufactures and markets therapies made from human plasma, including immunoglobulins, albumin and coagulation factors used to treat immune deficiencies, bleeding disorders and other chronic conditions.
Grifols operates a vertically integrated plasma business that includes plasma donation centers, collection and fractionation facilities, research and development, manufacturing and distribution.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
The article " Grifols Q3 Earnings Call Highlights " was originally published by MarketBeat.
